WO2010056059A3 - Novel crystalline dexlansoprazole and pharmaceutical composition comprising same - Google Patents

Novel crystalline dexlansoprazole and pharmaceutical composition comprising same Download PDF

Info

Publication number
WO2010056059A3
WO2010056059A3 PCT/KR2009/006678 KR2009006678W WO2010056059A3 WO 2010056059 A3 WO2010056059 A3 WO 2010056059A3 KR 2009006678 W KR2009006678 W KR 2009006678W WO 2010056059 A3 WO2010056059 A3 WO 2010056059A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
same
novel crystalline
crystalline dexlansoprazole
dexlansoprazole
Prior art date
Application number
PCT/KR2009/006678
Other languages
French (fr)
Other versions
WO2010056059A2 (en
Inventor
Sun Young Jang
Tai Won Kim
Sungbum Kim
Byung-Ku Kim
Soohwa Cho
Tae Hee Ha
Kwee Hyun Suh
Gwan Sun Lee
Original Assignee
Hanmi Pharm. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm. Co., Ltd. filed Critical Hanmi Pharm. Co., Ltd.
Priority to KR1020117013635A priority Critical patent/KR101321055B1/en
Publication of WO2010056059A2 publication Critical patent/WO2010056059A2/en
Publication of WO2010056059A3 publication Critical patent/WO2010056059A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A crystalline (+)-lansoprazole, whose X-ray diffraction spectrum comprises a major peak having a relative intensity of at least 20 % at an interplanar distance (d value) of 17.4 A, is homogeneous, non-hygroscopic, and stable, and a pharmaceutical composition comprising said crystal is effective for treating or preventing gastric acid-related diseases.
PCT/KR2009/006678 2008-11-14 2009-11-13 Novel crystalline dexlansoprazole and pharmaceutical composition comprising same WO2010056059A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020117013635A KR101321055B1 (en) 2008-11-14 2009-11-13 Novel crystalline dexlansoprazole and pharmaceutical composition comprising same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080113507 2008-11-14
KR10-2008-0113507 2008-11-14

Publications (2)

Publication Number Publication Date
WO2010056059A2 WO2010056059A2 (en) 2010-05-20
WO2010056059A3 true WO2010056059A3 (en) 2010-07-29

Family

ID=42170531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006678 WO2010056059A2 (en) 2008-11-14 2009-11-13 Novel crystalline dexlansoprazole and pharmaceutical composition comprising same

Country Status (2)

Country Link
KR (1) KR101321055B1 (en)
WO (1) WO2010056059A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095859A1 (en) * 2011-01-12 2012-07-19 Hetero Research Foundation Polymorphs of dexlansoprazole salts
WO2012176140A1 (en) * 2011-06-21 2012-12-27 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106279107A (en) * 2016-08-10 2017-01-04 成都尚药科技有限公司 A kind of preparation method of Dexlansoprazole crystal formation
CN106749182A (en) * 2016-11-08 2017-05-31 山东裕欣药业有限公司 A kind of Dexlansoprazole crystal-form compound and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462058B1 (en) * 1999-06-17 2002-10-08 Takeda Chemical Industries, Ltd. Benzimidazole compound crystal
US6608092B1 (en) * 1999-06-30 2003-08-19 Takeda Chemical Industries, Ltd. Crystals of benzimidazole compounds
US7285668B2 (en) * 2000-12-01 2007-10-23 Takeda Pharmaceutical Company Limited Process for the crystallization of (R)- or (S)-lansoprazole
EP1889841A1 (en) * 2005-06-07 2008-02-20 Takeda Pharmaceutical Company Limited Crystal of salt of benzimidazole compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462058B1 (en) * 1999-06-17 2002-10-08 Takeda Chemical Industries, Ltd. Benzimidazole compound crystal
US6608092B1 (en) * 1999-06-30 2003-08-19 Takeda Chemical Industries, Ltd. Crystals of benzimidazole compounds
US7285668B2 (en) * 2000-12-01 2007-10-23 Takeda Pharmaceutical Company Limited Process for the crystallization of (R)- or (S)-lansoprazole
EP1889841A1 (en) * 2005-06-07 2008-02-20 Takeda Pharmaceutical Company Limited Crystal of salt of benzimidazole compound

Also Published As

Publication number Publication date
KR20110086607A (en) 2011-07-28
KR101321055B1 (en) 2013-10-23
WO2010056059A2 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
WO2010056059A3 (en) Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2008079339A3 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
WO2007117778A3 (en) Quinolones useful as inducible nitric oxide synthase inhibitors
WO2010022055A3 (en) 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
EA200601273A1 (en) NEW CRYSTAL FORM V AGOMELATIN, THE METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS
WO2006104668A3 (en) Composition and methods for the treatment of proliferative diseases
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2005117867A3 (en) Monocyclic heterocycles as kinase inhibitors
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2009010139A3 (en) Quinazolinamide derivatives
EA200802119A1 (en) NEW CRYSTAL FORM VI OF AGOMELATIN, THE METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS
IL196543A (en) Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
MX2009006630A (en) 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors.
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2008135826A3 (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2010002655A3 (en) Pyrimidine derivatives as kinase inhibitors
EA200601271A1 (en) NEW CRYSTAL FORM IV OF AGOMELATIN, THE METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2008073452A8 (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
WO2009158431A3 (en) Pyrimidine derivatives as kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09826291

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20117013635

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 09826291

Country of ref document: EP

Kind code of ref document: A2